Biochemical and Mass Spectrometric Characterization of Human N-acylethanolamine-hydrolyzing Acid Amidase Inhibition

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Sep 7

PMID 22952796

Citations 9

Authors

Jay M West

Nikolai Zvonok

Kyle M Whitten

Subramanian K Vadivel

Anna L Bowman

Alexandros Makriyannis

Affiliations

Soon will be listed here.

Abstract

The mechanism of inactivation of human enzyme N-acylethanolamine-hydrolyzing acid amidase (hNAAA), with selected inhibitors identified in a novel fluorescent based assay developed for characterization of both reversible and irreversible inhibitors, was investigated kinetically and using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). 1-Isothiocyanatopentadecane (AM9023) was found to be a potent, selective and reversible hNAAA inhibitor, while two others, 5-((biphenyl-4-yl)methyl)-N,N-dimethyl-2H-tetrazole-2-carboxamide (AM6701) and N-Benzyloxycarbonyl-L-serine β-lactone (N-Cbz-serine β-lactone), inhibited hNAAA in a covalent and irreversible manner. MS analysis of the hNAAA/covalent inhibitor complexes identified modification only of the N-terminal cysteine (Cys126) of the β-subunit, confirming a suggested mechanism of hNAAA inactivation by the β-lactone containing inhibitors. These experiments provide direct evidence of the key role of Cys126 in hNAAA inactivation by different classes of covalent inhibitors, confirming the essential role of cysteine for catalysis and inhibition in this cysteine N-terminal nucleophile hydrolase enzyme. They also provide a methodology for the rapid screening and characterization of large libraries of compounds as potential inhibitors of NAAA, and subsequent characterization or their mechanism through MALDI-TOF MS based bottom up-proteomics.

Citing Articles

Fluorescence-Based Enzyme Activity Assay: Ascertaining the Activity and Inhibition of Endocannabinoid Hydrolytic Enzymes.

Ciuffreda P, Xynomilakis O, Casati S, Ottria R Int J Mol Sci. 2024; 25(14).

PMID: 39062935 PMC: 11276806. DOI: 10.3390/ijms25147693.

N-Acylethanolamine acid amidase (NAAA) is dysregulated in colorectal cancer patients and its inhibition reduces experimental cancer growth.

Romano B, Pagano E, Iannotti F, Piscitelli F, Brancaleone V, Lucariello G Br J Pharmacol. 2021; 179(8):1679-1694.

PMID: 34791641 PMC: 9303321. DOI: 10.1111/bph.15737.

Natural Potent NAAA Inhibitor Atractylodin Counteracts LPS-Induced Microglial Activation.

Yang L, Ji C, Li Y, Hu F, Zhang F, Zhang H Front Pharmacol. 2020; 11:577319.

PMID: 33117168 PMC: 7565389. DOI: 10.3389/fphar.2020.577319.

Molecular mechanism of activation of the immunoregulatory amidase NAAA.

Gorelik A, Gebai A, Illes K, Piomelli D, Nagar B Proc Natl Acad Sci U S A. 2018; 115(43):E10032-E10040.

PMID: 30301806 PMC: 6205464. DOI: 10.1073/pnas.1811759115.

Secretion, isotopic labeling and deglycosylation of N-acylethanolamine acid amidase for biophysical studies.

Pavlopoulos S, Pelekoudas D, Benchama O, Rawlins C, Agar J, West J Protein Expr Purif. 2017; 145:108-117.

PMID: 29253688 PMC: 6022831. DOI: 10.1016/j.pep.2017.12.005.

References

Zvonok N, Pandarinathan L, Williams J, Johnston M, Karageorgos I, Janero D . Covalent inhibitors of human monoacylglycerol lipase: ligand-assisted characterization of the catalytic site by mass spectrometry and mutational analysis. Chem Biol. 2008; 15(8):854-62. PMC: 3972761. DOI: 10.1016/j.chembiol.2008.06.008. View

Solorzano C, Zhu C, Battista N, Astarita G, Lodola A, Rivara S . Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc Natl Acad Sci U S A. 2009; 106(49):20966-71. PMC: 2791595. DOI: 10.1073/pnas.0907417106. View

Ahn K, Johnson D, Mileni M, Beidler D, Long J, McKinney M . Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol. 2009; 16(4):411-20. PMC: 2692831. DOI: 10.1016/j.chembiol.2009.02.013. View

Saario S, Laitinen J . Monoglyceride lipase as an enzyme hydrolyzing 2-arachidonoylglycerol. Chem Biodivers. 2007; 4(8):1903-13. DOI: 10.1002/cbdv.200790158. View

Jones D . Protein secondary structure prediction based on position-specific scoring matrices. J Mol Biol. 1999; 292(2):195-202. DOI: 10.1006/jmbi.1999.3091. View

Solorzano C, Antonietti F, Duranti A, Tontini A, Rivara S, Lodola A . Synthesis and structure-activity relationships of N-(2-oxo-3-oxetanyl)amides as N-acylethanolamine-hydrolyzing acid amidase inhibitors. J Med Chem. 2010; 53(15):5770-81. PMC: 2932887. DOI: 10.1021/jm100582w. View

Picone R, Khanolkar A, Xu W, Ayotte L, Thakur G, Hurst D . (-)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. Mol Pharmacol. 2005; 68(6):1623-35. DOI: 10.1124/mol.105.014407. View

Mileni M, Johnson D, Wang Z, Everdeen D, Liimatta M, Pabst B . Structure-guided inhibitor design for human FAAH by interspecies active site conversion. Proc Natl Acad Sci U S A. 2008; 105(35):12820-4. PMC: 2529035. DOI: 10.1073/pnas.0806121105. View

Armirotti A, Romeo E, Ponzano S, Mengatto L, Dionisi M, Karacsonyi C . β-Lactones Inhibit N-acylethanolamine Acid Amidase by S-Acylation of the Catalytic N-Terminal Cysteine. ACS Med Chem Lett. 2014; 3(5):422-6. PMC: 4025845. DOI: 10.1021/ml300056y. View

10.

Lodola A, Branduardi D, De Vivo M, Capoferri L, Mor M, Piomelli D . A catalytic mechanism for cysteine N-terminal nucleophile hydrolases, as revealed by free energy simulations. PLoS One. 2012; 7(2):e32397. PMC: 3289653. DOI: 10.1371/journal.pone.0032397. View

11.

Bernardo K, HURWITZ R, Zenk T, Desnick R, Ferlinz K, Schuchman E . Purification, characterization, and biosynthesis of human acid ceramidase. J Biol Chem. 1995; 270(19):11098-102. DOI: 10.1074/jbc.270.19.11098. View

12.

Zhao L, Tsuboi K, Okamoto Y, Nagahata S, Ueda N . Proteolytic activation and glycosylation of N-acylethanolamine-hydrolyzing acid amidase, a lysosomal enzyme involved in the endocannabinoid metabolism. Biochim Biophys Acta. 2007; 1771(11):1397-405. DOI: 10.1016/j.bbalip.2007.10.002. View

13.

Ramarao M, Murphy E, Shen M, Wang Y, Bushell K, Huang N . A fluorescence-based assay for fatty acid amide hydrolase compatible with high-throughput screening. Anal Biochem. 2005; 343(1):143-51. DOI: 10.1016/j.ab.2005.04.032. View

14.

West J, Zvonok N, Whitten K, Wood J, Makriyannis A . Mass spectrometric characterization of human N-acylethanolamine-hydrolyzing acid amidase. J Proteome Res. 2011; 11(2):972-81. PMC: 3706083. DOI: 10.1021/pr200735a. View

15.

Kitz R, Wilson I . Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem. 1962; 237:3245-9. View

16.

Saario S, Laitinen J . Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors. Basic Clin Pharmacol Toxicol. 2007; 101(5):287-93. DOI: 10.1111/j.1742-7843.2007.00130.x. View

17.

Morse K, Fournier D, Li X, Grzybowska J, Makriyannis A . A novel electrophilic high affinity irreversible probe for the cannabinoid receptor. Life Sci. 1995; 56(23-24):1957-62. DOI: 10.1016/0024-3205(95)00176-7. View

18.

Brannigan J, Dodson G, Duggleby H, Moody P, Smith J, Tomchick D . A protein catalytic framework with an N-terminal nucleophile is capable of self-activation. Nature. 1995; 378(6555):416-9. DOI: 10.1038/378416a0. View

19.

Godlewski G, Offertaler L, Wagner J, Kunos G . Receptors for acylethanolamides-GPR55 and GPR119. Prostaglandins Other Lipid Mediat. 2009; 89(3-4):105-11. PMC: 2751869. DOI: 10.1016/j.prostaglandins.2009.07.001. View

20.

Tsuboi K, Takezaki N, Ueda N . The N-acylethanolamine-hydrolyzing acid amidase (NAAA). Chem Biodivers. 2007; 4(8):1914-25. DOI: 10.1002/cbdv.200790159. View